| Protein Name: | Uroporphyrinogen decarboxylase (P06132) |
|---|---|
| Gene Name: | UROD |
| Description: | Uroporphyrinogen decarboxylase (EC 4 1 1 37) (URO-D) (UPD) |
| PDB ID: | 1JPH |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Cyclophosphamide | Dark Urine | Hepatic uroporphyrinogen decarboxylase activity is markedly reduced in patients with the disorder of porphyria cutanea tarda@ a metabolic disorder of heme biosynthesis@characterized by dark urine. [ ADR Type 1 ] | Development of porphyria cutanea tarda after treatment with cyclophosphamide |
| Cyclophosphamide | Excess Porphyrin | Hepatic uroporphyrinogen decarboxylase activity is markedly reduced in patients with the disorder of porphyria cutanea tarda@ a metabolic disorder of heme biosynthesis@characterized by distinctive pattern of excess porphyrin production. [ ADR Type 1 ] | Development of porphyria cutanea tarda after treatment with cyclophosphamide |
| Cyclophosphamide | Facial Hypertrichosis | Hepatic uroporphyrinogen decarboxylase activity is markedly reduced in patients with the disorder of porphyria cutanea tarda@ a metabolic disorder of heme biosynthesis@ characterized by facial hypertrichosis. [ ADR Type 1 ] | Development of porphyria cutanea tarda after treatment with cyclophosphamide |
| Cyclophosphamide | Hyperpigmentation | Hepatic uroporphyrinogen decarboxylase activity is markedly reduced in patients with the disorder of porphyria cutanea tarda@ a metabolic disorder of heme biosynthesis@characterized by cutaneous hyperpigmentation [ ADR Type 1 ] | Development of porphyria cutanea tarda after treatment with cyclophosphamide |
This panel provides information on drug category
| Toxicity | Source |
|---|